Iatrogenic hookworm therapy shows promise for treating disorders that result from 27 a dysregulated immune system, including inflammatory bowel disease (IBD). Here we use a 28 metabolomics approach to characterize the non-protein small molecule complement of 29 hookworms. Gas chromatography-mass spectrometry and liquid chromatography-mass 30 spectrometry analyses of somatic tissue extracts revealed the presence of 52 polar metabolites 31 and 22 non-polar components including short chain fatty acids (SCFA). Several of these small 32 metabolites, notably the SCFA, have been shown to have anti-inflammatory properties in various 33 diseases, including IBD. Using a murine model of colitis and human peripheral blood 34 mononuclear cells, we demonstrate that somatic tissue extracts of the hookworm Ancylostoma 35 caninum contain small molecules with anti-inflammatory activities. Of the five extracts tested, 36 two of them significantly protected mice against T cell-mediated immunopathology and weight 37 loss in a chemically-induced colitis model. Moreover, one of the anti-colitic extracts suppressed 38 ex vivo production of inflammatory cytokines from primary human leukocytes. While the origin 39 of the SCFA (parasite or host microbiota-derived) present in the hookworm somatic tissue 40 extracts cannot be ascertained from this study, it is possible that A. caninum may be actively 41 promoting an anti-inflammatory host microbiome by facilitating immune crosstalk through SCFA 42 production. 43 44 Short chain fatty acids; GC-MS; Metabolome 46 47 48 49 50 3 51 52Inflammatory Bowel Disease (IBD) is associated with chronic inflammation of the 53 digestive tract, and primarily includes ulcerative colitis (UC) and Crohn's disease (CD). The 54 etiology of IBD is not well established but it is usually characterized by inflammation, loss of 55 appetite and weight, chronic diarrhea, bloody stools, fever, rectal bleeding, abdominal pain, 56 fatigue, and anemia (1-3). IBD has been linked to many extra-intestinal manifestations (4) and 57 implicated with mental health problems (5). Current treatments for IBD include, 5-58 aminosalicylates, glucocorticosteroids, immunomodulators and biologics, and proctocolectomy 59 as a last resort when drug treatment fails. Many of these drugs are often associated with side-60 effects and various postoperative complications (6, 7). Frontline biologics such as treatment with 61 anti-TNF monoclonal antibodies are only efficacious in some patients and treatment does not 62 result in long term cure (8). Failure of these frontline treatments is associated with elevated risk 63 of colon cancer, and can result in the need for surgical removal of the colon (partial or full). 64There is therefore an urgent need for new and effective anti-inflammatory drugs to treat IBD. 65Guided by millennia of host-parasite co-evolution, we (9-13) and others (14-16) have 66 demonstrated the therapeutic properties of experimental hookworm infection to treat 67 gastrointestinal (GI) inflammatory diseases. Hookworms resident in ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.